Status:
COMPLETED
The Effects of Sacubitril/Valsartan on the Heart Functions
Lead Sponsor:
The Young Investigator Group of Cardiovascular Research
Conditions:
Drug Effect
Eligibility:
All Genders
18+ years
Brief Summary
Background: Sacubitril/valsartan, has been found to be more beneficial than enalapril for reducing the incidences of sudden cardiac death, death from worsening heart failure (HF), and hospitalization...
Eligibility Criteria
Inclusion
- Age is more than or equal 18 years old
- Able to provide written informed consent
- Indicated for the use of sacubitril/valsartan as recommended by the European Society of Cardiology (ESC) heart failure guidelines 2016
- Left ventricular ejection fraction of 40% or less
Exclusion
- Cardiac resynchronization therapy (CRT) device implantation less than 3 months prior to the start of this study or CRT implantation intentions
- Atrial fibrillation
- Poor echocardiographic images
- Sacubitril/valsartan treatment intolerance during the follow-up period
Key Trial Info
Start Date :
January 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2018
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03830814
Start Date
January 1 2017
End Date
July 31 2018
Last Update
February 5 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.